Mucopolysaccharidosis type I: Current treatments, limitations and prospects for improvement

Christiane S. Hampe, Jacob Wesley, Troy C. Lund, Paul J. Orchard, Lynda E. Polgreen, Julie B. Eisengart, Linda K. McLoon, Sebahattin Cureoglu, Patricia Schachern, R. Scott McIvor

Research output: Contribution to journalReview articlepeer-review

Abstract

Mucopolysaccharidosis type I (MPS I) is a lysosomal disease, caused by a deficiency of the enzyme alpha-L-iduronidase (IDUA). IDUA catalyzes the degradation of the glycosaminoglycans dermatan and heparan sulfate (DS and HS, respectively). Lack of the enzyme leads to pathologic accumulation of undegraded HS and DS with subsequent disease manifestations in multiple organs. The disease can be divided into severe (Hurler syndrome) and attenuated (Hurler-Scheie, Scheie) forms. Currently approved treatments consist of enzyme replacement therapy (ERT) and/or hematopoietic stem cell transplantation (HSCT). Patients with attenuated disease are often treated with ERT alone, while the recommended therapy for patients with Hurler syndrome consists of HSCT. While these treatments significantly improve disease manifestations and prolong life, a considerable burden of disease remains. Notably, treatment can partially prevent, but not significantly improve, clinical manifestations, necessitating early diagnosis of disease and commencement of treatment. This review discusses these standard therapies and their impact on common disease manifestations in patients with MPS I. Where relevant, results of animal models of MPS I will be included. Finally, we highlight alternative and emerging treatments for the most common disease manifestations.

Original languageEnglish (US)
Article number189
Pages (from-to)1-25
Number of pages25
JournalBiomolecules
Volume11
Issue number2
DOIs
StatePublished - Jan 29 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors.

Keywords

  • Animal models
  • Enzyme replacement therapy
  • Experimental therapies
  • Hematopoietic stem cell transplantations
  • Hurler syndrome
  • Mucopolysaccharidosis type i

Fingerprint

Dive into the research topics of 'Mucopolysaccharidosis type I: Current treatments, limitations and prospects for improvement'. Together they form a unique fingerprint.

Cite this